Epizyme (NASDAQ: EPZM)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-08 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.360 | -0.210 | 0.1500 | ||||
REV | 10.200M | 27.528M | 17.328M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Epizyme (NASDAQ: EPZM) through any online brokerage.
There are no as such competitors for Epizyme.
The latest price target for Epizyme (NASDAQ: EPZM) was reported by Cowen & Co. on Tuesday, June 28, 2022. The analyst firm set a price target for 1.50 expecting EPZM to rise to within 12 months (a possible 2.04% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Epizyme (NASDAQ: EPZM) is $1.47 last updated August 11, 2022, 8:00 PM UTC.
There are no upcoming dividends for Epizyme.
Epizyme’s Q3 earnings are confirmed for Tuesday, November 8, 2022.
There is no upcoming split for Epizyme.
Epizyme is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.